Respiratory

Treatments for asthma, COPD, cystic fibrosis, idiopathic pulmonary fibrosis, and other lung diseases.

Companies

Pipeline Drugs

745

Key People

787

Respiratory Pipeline (745 drugs)

Commercial: 137Phase 2: 57Pre-clinical: 57Approved: 56Phase 3: 47Preclinical: 43Marketed: 22Phase 1: 21Phase III: 21Development: 18Not Specified: 11Market: 10Research: 9Phase II: 6Not Disclosed: 6Early Phase: 6Launched: 5Phase 2b: 5Clinical Research: 5Clinical Trials: 5Clinical: 5Commercial (Continuous Development): 5Filed: 4Reference Standard: 4Various: 4Commercial Model: 4Clinical Development: 4Development/Validation: 4Discovery: 4Not Disclosed/Partner Dependent: 4Commercial Development: 3Phase 1/2: 3Ongoing Development: 3Discovery/Preclinical: 3Pivotal: 3Pre-clinical/Research: 3Development/Commercial: 3Clinical Validation: 3Launch: 3ANDA Filed/Approved: 3Phase I/II: 3Undisclosed Preclinical/Discovery: 3Commercial Launch: 2Approved (Tentative): 2Pilot: 2Discovery/Pre-clinical: 2NDA Submitted: 2Phase 2/3: 2NA: 2Service: 2Phase 2a: 2Commercial/Development: 2Validated/Commercial: 2Bioequivalence: 2Commercial (licensed): 2Regulatory Review: 2Phase 1b/2: 2Phase 1b/2a: 1Commercial (Approved): 1R&D: 1Evidence Generation: 1commercial: 1ANDA Filed / Development: 1ANDA Pending / Development: 1Marketed / Line Extensions: 1Approved / Marketed: 1Phase Ib/IIa: 1Phase 1/2 (pilot): 1Phase 2 (observational): 1Pre-clinical/Clinical: 1FDA Approved: 1Exploratory: 1Platform: 1Pre‑clinical: 1Phase-3: 1Phase-2: 1Development/ANVISA Submission: 1Pilot Study: 1Research/Discovery: 1Research/Pre-clinical: 1Emergency Use Authorization / Pre-market Approval: 1Phase 1b: 1Pre-IND: 1Development Stage (Pre-clinical): 1Development Stage: 1Pre-commercial: 1Not Disclosed (Likely Pre-clinical/Early Clinical): 1FDA Submission: 1Clinical Trial: 1Approved/RUO: 1Feasibility: 1Approved/Clinical: 1NDA: 1Device Development: 1Phase 2b/3: 1NDA Submission: 1ANDA Submission: 1Clinical-stage (Phase not specified): 1Pre-clinical / Early Feasibility: 1Commercialization: 1N/A (Service): 1Research/Development: 1Implementation: 1Research to Clinical: 1Commercial (Recent Acquisition): 1Commercial / Lifecycle Management: 1Not Specified (Device Pathway): 1Commercial (World's First Claim): 1Pre-clinical through Commercial: 1Commercial (Out-licensing): 1N/A: 1Pivotal (FDA IDE): 1Pre-launch: 1Phase 4: 1Pre-clinical/Phase 1: 1Preclinical/CMC Development: 1Lead Optimization: 1Pre-clinical/Phase 2: 1Non-clinical: 1Approved (via voluntary license): 1Regulatory clearance (FDA cleared for spirometry & plethysmography): 1FDA cleared (510(k)): 1Concept: 1Phase III / Registration: 1Early Development: 1Phase III / Marketed: 1Registration: 1Commercial & Development: 1Development & Commercial: 1Commercial & Line Extensions: 1Phase 1-3: 1Research to Phase 3: 1Phase 2 (assumed): 1Research / Pre-clinical: 1Discovery / Research: 1Phase I: 1NDA Filed: 1Marketed / Phase 3: 1Registration & Launch: 1Development & Registration: 1Technology Transfer & Localization: 1Exploratory / Early Development: 1Out-licensed: 1Preclinical/Discovery: 1Launch Preparation: 1Research/Preclinical: 1Approved (China NMPA Review): 1

Drug	Company	Indication	Phase	Status
PanCytoVir™ (oral probenecid)	TrippBio	COVID-19	Phase 2	Active
Penthrox® (methoxyflurane)	Medical Developments International	Acute procedural and trauma pain	Commercial	Active
Penthrox® Pediatric Indication	Medical Developments International	Acute pain in children	Commercial	Active
Breath‑A‑Tech® Spacer Series	Medical Developments International	Asthma and COPD inhaler delivery	Commercial	Active
EasyScreen™ Gastrointestinal Parasite Detection Kit	Genetic Signatures	Gastrointestinal parasites	Commercial	Active
EasyScreen™ Respiratory Virus Panel	Genetic Signatures	Respiratory viral infections	Commercial	Active
EasyScreen™ Enteric Pathogen Panel	Genetic Signatures	Enteric bacterial and viral pathogens	Commercial	Active
PUR3100	Pulmatrix	Acute Migraine	Phase 2	Active
PUR1800	Pulmatrix	Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)	Phase 1b/2a	Active
PUR1900	Pulmatrix	Allergic Bronchopulmonary Aspergillosis (ABPA) in Asthma / Cystic Fibrosis	Phase 2	Active
PUR0200	Pulmatrix	Chronic Obstructive Pulmonary Disease (COPD)	Preclinical	Active
sCD146 CLIA Assay	YHLO Biotech	Biomarker (Cardiovascular/Kidney)	Commercial (Approved)	Launched
Blood Bank Panel	YHLO Biotech	Blood Screening	Commercial	IVDR CE Certified
Type 1 Diabetes Ecosystem	YHLO Biotech	Diabetes Diagnosis/Management	Commercial Development	Partnership (Sanofi)
iTLA mini Plus / iBC 900	YHLO Biotech	Laboratory Automation	Commercial	Launched
Nasodine Nasal Spray	Firebrick Pharma	Common Cold (respiratory viral infection)	Commercial	Active
Nasodine Throat Spray	Firebrick Pharma	Sore throat / Upper respiratory viral infection (incl. COVID‑19)	Commercial	Active
INNA-051	ENA Respiratory	Prophylaxis against viral respiratory infections (e.g., SARS‑CoV‑2, influenza, rhinovirus)	Phase 2	Active
SmartVest Clearway System	Electromed	Bronchiectasis, COPD, Impaired Airway Clearance	Commercial	Launched (2023)
Next-Generation Product Development	Electromed	Platform Enhancements	R&D	Active
Clinical Evidence Expansion	Electromed	Bronchiectasis, COPD, Post-COVID Sequelae	Evidence Generation	Active
Technegas® for Pulmonary Embolism	Cyclomedica	Pulmonary Embolism	commercial	Active
Technegas® for COPD	Cyclomedica	Chronic Obstructive Pulmonary Disease	Phase 2	Active
Technegas® for Asthma	Cyclomedica	Asthma	Phase 2	Active
Technegas® for CTEPH	Cyclomedica	Chronic Thromboembolic Pulmonary Hypertension	Phase 2	Active
Technegas® for Radiotherapy Planning	Cyclomedica	Pre‑operative Quantification & Radiotherapy Planning	Phase 2	Active
Authorized Generic of Nucynta® ER (tapentadol)	hikma	Pain Management	Launched	Launched (March 2026)
Authorized Generic of Nucynta® (tapentadol)	hikma	Pain Management	Launched	Launched (February 2026)
Complex Generic Injectables Portfolio	hikma	Various (Oncology Support, Anti-infectives, CNS)	ANDA Filed / Development	Active
Oral Solid Dose Generics Portfolio	hikma	Various (CV, CNS, Diabetes)	ANDA Pending / Development	Active
Branded Specialty Portfolio (MENA)	hikma	Oncology, Diabetes, Cardiovascular, Respiratory	Marketed / Line Extensions	Active
Elyea (relugolix combo)	Organon (2)	Heavy Menstrual Bleeding with Uterine Fibroids; Endometriosis Pain	Approved	Launched / Commercial Growth
Phexxi	Organon (2)	Non-hormonal Contraceptive	Approved	Launched / Commercial Growth
Orilissa (elagolix)	Organon (2)	Endometriosis Pain	Approved	Launched / Commercial Growth
Biosimilar Aflibercept	Organon (2)	Ophthalmology (nAMD, DME)	Filed	Under Regulatory Review
Biosimilar Denosumab	Organon (2)	Osteoporosis, Bone Metastasis	Phase 3	Active
Biosimilar Ranibizumab	Organon (2)	Ophthalmology (nAMD, DME, RVO)	Phase 3	Active
Biosimilar Ustekinumab	Organon (2)	Plaque Psoriasis, Psoriatic Arthritis, IBD	Phase 3	Active
Biosimilar Bevacizumab	Organon (2)	Oncology	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Oncology	Phase 3	Active
OPN-401	Organon (2)	Recurrent Pregnancy Loss	Phase 2b	Active
Cardiovascular & Cerebrovascular Products	Universe Pharmaceuticals	Hyperlipidemia, circulation support	Commercial	Active
Respiratory & Cold Relief Products	Universe Pharmaceuticals	Cough, common cold	Commercial	Active
Internal Medicine Products	Universe Pharmaceuticals	General internal medicine disorders	Commercial	Active
Gynecology Products	Universe Pharmaceuticals	Women's health conditions	Commercial	Active
New Dosage Form Development	Universe Pharmaceuticals	Various	Development	Active
New TCM Formula Registration	Universe Pharmaceuticals	Various	Development	Active
Zeqmelit® (Dexamethasone oral film)	AcuCort	Severe acute allergic reactions (e.g., anaphylaxis)	Approved / Marketed	Commercial
LTX-109 nasal spray	Pharma Holdings	Therapeutic against influenza and similar illnesses	Phase Ib/IIa	Active
LTX-109 inhaled form	Pharma Holdings	Respiratory tract infections (formulation development)	Pre-clinical	Active